Enliven Therapeutics CSO sells shares worth $135,697

Enliven Therapeutics NASDAQ:ELVN Chief Scientific Officer Joseph P Lyssikatos reported selling 7,000 shares of common stock on September 19, 2025. The sales were executed in two tranches, with prices ranging from $19.1095 to $20.016, resulting in a total transaction value of $135,697. The transaction comes as the stock shows strong momentum, posting an 8% gain over the past week, according to InvestingPro data.

The first sale involved 4,870 shares sold at a weighted average price of $19.1095, with individual prices ranging from $18.94 to $19.89. The second sale consisted of 2,130 shares at a weighted average price of $20.016, with prices ranging from $19.95 to $20.0469. The current market values Enliven at $1.14 billion, with analysts setting price targets between $33 and $52.

Following these transactions, Lyssikatos indirectly holds 933,188 shares through The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee. The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024. InvestingPro analysis shows the company maintains a Fair overall financial health rating, with particularly strong scores in cash flow management. Subscribers can access additional insights and 6 more ProTips about ELVN’s financial position.

In other recent news, Enliven Therapeutics has been the focus of attention from multiple analyst firms. H.C. Wainwright has increased its price target for the company from $40 to $48 while maintaining a Buy rating. This upgrade comes after the company presented updated results from its Phase 1a/1b ENABLE trial at EHA 2025, which evaluates the effectiveness of ELVN-001 in patients with chronic myelogenous leukemia. Additionally, BTIG has reiterated its Buy rating with a $45 price target, highlighting the potential of ELVN-001 as a next-generation tyrosine kinase inhibitor. These recent developments underscore the promising outlook for ELVN-001 in the treatment of chronic myeloid leukemia. Both firms have shown confidence in Enliven Therapeutics’ ongoing clinical trials and market potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.